Institution
Monash University
Education•Melbourne, Victoria, Australia•
About: Monash University is a education organization based out in Melbourne, Victoria, Australia. It is known for research contribution in the topics: Population & Poison control. The organization has 35920 authors who have published 100681 publications receiving 3027002 citations.
Papers published on a yearly basis
Papers
More filters
TL;DR: BIS-guided anaesthesia reduces the risk of awareness in at-risk adult surgical patients undergoing relaxant general anaesthesia, and with a cost of routine BIS monitoring at US16 dollars per use in Australia and a number needed to treat of 138, the cost of preventing one case ofawareness in high-risk patients is about 2200 dollars.
1,099 citations
Fraunhofer Society1, University of Manchester2, ETH Zurich3, Eindhoven University of Technology4, Erasmus University Rotterdam5, Chalmers University of Technology6, Lund University7, Vanderbilt University8, Aalto University9, University of Brighton10, University of Sussex11, École Polytechnique Fédérale de Lausanne12, Stockholm Environment Institute13, Université libre de Bruxelles14, Monash University15, Linköping University16, King's College London17, Cardiff University18
TL;DR: In this article, the authors provide an extensive review and an updated research agenda for the field, classified into nine main themes: understanding transitions; power, agency and politics; governing transitions; civil society, culture and social movements; businesses and industries; transitions in practice and everyday life; geography of transitions; ethical aspects; and methodologies.
Abstract: Research on sustainability transitions has expanded rapidly in the last ten years, diversified in terms of topics and geographical applications, and deepened with respect to theories and methods. This article provides an extensive review and an updated research agenda for the field, classified into nine main themes: understanding transitions; power, agency and politics; governing transitions; civil society, culture and social movements; businesses and industries; transitions in practice and everyday life; geography of transitions; ethical aspects; and methodologies. The review shows that the scope of sustainability transitions research has broadened and connections to established disciplines have grown stronger. At the same time, we see that the grand challenges related to sustainability remain unsolved, calling for continued efforts and an acceleration of ongoing transitions. Transition studies can play a key role in this regard by creating new perspectives, approaches and understanding and helping to move society in the direction of sustainability.
1,099 citations
McMaster University1, University of Montpellier2, Transylvania University3, Ghent University Hospital4, University of Sydney5, Humanitas University6, University of South Florida7, Leiden University Medical Center8, RMIT University9, Federal University of Bahia10, Pierre-and-Marie-Curie University11, Saint Louis University12, University of Porto13, Katholieke Universiteit Leuven14, Medical University of Łódź15, University of Tartu16, Oslo University Hospital17, Royal College of Surgeons in Ireland18, University of California, San Diego19, University of Barcelona20, University of Padua21, Monash University22, Charles University in Prague23, University of Manchester24, Ajou University25, University of Genoa26, Nippon Medical School27, University of Aberdeen28, University of Edinburgh29, Kerman Medical University30, Medical University of Warsaw31, National Institutes of Health32, Vilnius University33, University of Turku34, Nova Southeastern University35, Boston Children's Hospital36, Beijing Tongren Hospital37, Charité38
TL;DR: The 2016 revision of the ARIA guidelines provides both updated and new recommendations about the pharmacologic treatment of AR, addressing the relative merits of using oral H1‐antihistamines, intranasal H1-antihistsamines, IntranasAL corticosteroids, and leukotriene receptor antagonists either alone or in combination.
Abstract: Background Allergic rhinitis (AR) affects 10% to 40% of the population. It reduces quality of life and school and work performance and is a frequent reason for office visits in general practice. Medical costs are large, but avoidable costs associated with lost work productivity are even larger than those incurred by asthma. New evidence has accumulated since the last revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines in 2010, prompting its update. Objective We sought to provide a targeted update of the ARIA guidelines. Methods The ARIA guideline panel identified new clinical questions and selected questions requiring an update. We performed systematic reviews of health effects and the evidence about patients' values and preferences and resource requirements (up to June 2016). We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) evidence-to-decision frameworks to develop recommendations. Results The 2016 revision of the ARIA guidelines provides both updated and new recommendations about the pharmacologic treatment of AR. Specifically, it addresses the relative merits of using oral H1-antihistamines, intranasal H1-antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists either alone or in combination. The ARIA guideline panel provides specific recommendations for the choice of treatment and the rationale for the choice and discusses specific considerations that clinicians and patients might want to review to choose the management most appropriate for an individual patient. Conclusions Appropriate treatment of AR might improve patients' quality of life and school and work productivity. ARIA recommendations support patients, their caregivers, and health care providers in choosing the optimal treatment.
1,098 citations
University of Texas MD Anderson Cancer Center1, University of California, Davis2, City of Hope National Medical Center3, University of Chicago4, Harvard University5, Monash University6, University of Ulm7, University of Paris8, Université catholique de Louvain9, McMaster University10, University of Barcelona11, Peking Union Medical College12, University of Zagreb13, University of Ostrava14, University of Helsinki15, University of Debrecen16, University of Genoa17, Seoul National University18, Sungkyunkwan University19, China Medical University (Taiwan)20, Ondokuz Mayıs University21, Genentech22, AbbVie23, University of Pennsylvania24
TL;DR: In previously untreated patients with confirmed AML who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of remission was higher among patients who received azacitidine plus venetoclax than among those who received zsitidine alone.
Abstract: Background Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising effica...
1,097 citations
TL;DR: In this paper, the diagnostic performance of noninvasive fractional flow reserve (FFR) derived from standard acquired coronary computed tomography angiography (CTA) datasets for the diagnosis of myocardial ischemia in patients with suspected stable coronary artery disease (CAD) was evaluated.
1,094 citations
Authors
Showing all 36568 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Bert Vogelstein | 247 | 757 | 332094 |
| Kenneth W. Kinzler | 215 | 640 | 243944 |
| David J. Hunter | 213 | 1836 | 207050 |
| David R. Williams | 178 | 2034 | 138789 |
| Yang Yang | 171 | 2644 | 153049 |
| Lei Jiang | 170 | 2244 | 135205 |
| Dongyuan Zhao | 160 | 872 | 106451 |
| Christopher J. O'Donnell | 159 | 869 | 126278 |
| Leif Groop | 158 | 919 | 136056 |
| Mark E. Cooper | 158 | 1463 | 124887 |
| Theo Vos | 156 | 502 | 186409 |
| Mark J. Smyth | 153 | 713 | 88783 |
| Rinaldo Bellomo | 147 | 1714 | 120052 |
| Detlef Weigel | 142 | 516 | 84670 |
| Geoffrey Burnstock | 141 | 1488 | 99525 |